BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: BioCryst is a biopharmaceutical company focused on the discovery and development of novel small molecule drugs. The company has not yet commercialized any products and relies on collaborative agreements, government contracts, and equity financing to fund operations. Key programs include peramivir (influenza), forodesine HCl (cancer), and BCX-4208 (psoriasis).

Key Financial Metrics

Liquidity: As of September 30, 2007, the company held approximately $102.2 million in cash, cash equivalents, and marketable securities. Management projects a net cash burn of approximately $24.0 million for the full year 2007.

Material Changes vs. Prior Period

• Revenue Surge: Collaborative and other R&D revenues increased to $20.5 million for the quarter (from $1.8 million in Q3 2006) and $43.1 million for the nine-month period (from $4.1 million in 2006). This growth is primarily driven by a $102.6 million contract with the U.S. Department of Health and Human Services (HHS) for peramivir development and amortization of deferred revenue from collaborations with Roche and Shionogi.
• Expense Growth: R&D expenses increased 77.8% to $29.7 million for the quarter and 80.8% to $64.9 million for the nine months, driven by clinical trial costs, manufacturing, and personnel increases. G&A expenses rose 62.5% for the quarter due to headcount and professional fees.
• Financing Activity: In August 2007, the company completed a private placement raising approximately $65.3 million through the sale of 8.3 million shares and warrants. This significantly bolstered cash reserves compared to the prior year.
• Receivables: Receivables from collaborations increased significantly, with approximately $21 million in billed and unbilled receivables related to the HHS contract as of September 30, 2007.

Outlook, Risks, and Management Commentary

Guidance and Outlook: Management believes current resources, including the HHS contract and collaboration payments, are sufficient to fund operations for at least the next twelve months. However, the company expects to incur additional losses and will likely need to raise additional capital to complete the development and commercialization of its product candidates.

Clinical Updates:

• Peramivir: Phase II results for the intramuscular formulation showed a treatment effect over placebo but were not statistically significant. The company is analyzing data and planning a pivotal program. A Phase II trial for the intravenous formulation for hospitalized patients was initiated in July 2007.
• Forodesine HCl: A pivotal Phase II trial for cutaneous T-cell lymphoma (CTCL) began enrollment in October 2007. A previous trial for T-cell acute lymphoblastic leukemia was voluntarily put on hold to investigate particulates in the formulation.
• BCX-4208: Roche initiated a Phase II trial for psoriasis in July 2007.

Risks and Contingencies:

• HHS Contract Dependency: A significant portion of projected revenues and cash flow depends on reimbursement from the HHS contract. Delays, cost disallowances, or termination by the government would have a material negative impact.
• Clinical Trial Risks: The company faces standard risks regarding the safety and efficacy of drug candidates, patient enrollment, and regulatory approval.
• Financing Needs: Failure to secure additional funding could force the company to delay, scale back, or eliminate R&D programs.
• Collaboration Risks: Future revenues depend on partners (Roche, Mundipharma, Shionogi, Green Cross) fulfilling their obligations and achieving milestones.

Investor Verification Checklist

• HHS Contract Status: Verify the current status of the $102.6 million HHS contract, including any potential delays in reimbursement or cost disputes.
• Clinical Trial Results: Monitor the final analysis of the intramuscular peramivir Phase II trial and the progress of the pivotal intravenous and oral forodesine trials.
• Cash Burn Rate: Track the monthly cash burn rate against the projected $24.0 million annual burn to assess runway adequacy.
• Private Placement Registration: Confirm the registration status of the remaining 175,513 shares and warrants from the August 2007 private placement to avoid potential liquidated damages.
• Collaboration Milestones: Review progress on milestones with Roche, Mundipharma, and Shionogi that trigger future event payments.